(RTTNews) - BioArctic AB's partner Eisai Co., Ltd. (4523.T) presented long-term data from the Phase 3 Clarity AD trial showing that continuous treatment with LEQEMBI (lecanemab-irmb) provided sustained benefits in patients with early Alzheimer's disease.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.
